CytoMed Therapeutics Stock
CytoMed Therapeutics Limited
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Singapore
- CEO
- Chee Kong Choo
- Employees
- 42
- Market cap
- $10 M
- IPO
- 14/04/2023
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated…
CytoMed Therapeutics stock: price history
1D
+1.1%
1W
-1.1%
1M
-0.7%
6M
-12.9%
YTD
-34.3%
1Y
-60.9%
2Y
-57.7%
5Y
–
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~38% weaker price swings than usual
Ask the agents about CytoMed Therapeutics
Analyst assessment of CytoMed Therapeutics
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 10/10/2024
CytoMed Therapeutics stock metrics
P/E
-2.57
P/B
2.69
EV/EBITDA
-2.1
RETURN ON EQUITY
-35.7%
NET MARGIN
-1,125.6%
DEBT/EQUITY
0.09
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
30.4%
FLOAT SHARES
3,596,346
AVG. DAILY VOLUME (30D)
18,702
Insider transactions (SEC)
Choo Chee Kong
Choo Chee Kong
Choo Chee Kong
Comparable stocks
Frequently asked questions about CytoMed Therapeutics stock
What does CytoMed Therapeutics do?
CytoMed Therapeutics Limited is a company in the Healthcare sector, Biotechnology industry, headquartered in Singapore.
The CEO is Chee Kong Choo, the company employs around 42 people.
The IPO was on 14/04/2023; the stock trades on NASDAQ under the ticker GDTC.
What do analysts say about CytoMed Therapeutics stock?
1 analysts rate the stock, the consensus is Buy (as of 10/10/2024).
This is an external assessment, not a statement by Market Jury.
When does CytoMed Therapeutics report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -38% stronger than usual.
Does CytoMed Therapeutics pay a dividend?
No, CytoMed Therapeutics currently does not pay a dividend.
Which stocks are comparable to CytoMed Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get CytoMed Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess CytoMed Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.